Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme

Completed

Conditions studied: Glioblastoma

In brief

This study is for subjects with a diagnosis of a brain tumor called glioblastoma that is being treated with bevacizumab. This study will use a new MRI technique to compare the images of blood vessels and tumor structure to the effectiveness of bevacizumab.

Key facts

Study ID

NCT01604590

Run by

Medical University of South Carolina

People needed

13

Starts

2012-07-01

Expected to finish

2014-09-01

Last updated by the study team

2015-04-13

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age between 18 and 80 years of age
• Progressive glioblastoma patients who have been planned to receive bevacizumab
• Karnofsky Performance Status 50 or above (vd. Appendix A)
• Established pathologic diagnosis of glioblastoma
• Prior treatment with radiation and chemotherapy
• Neuroimaging progression of glioblastoma
• Able and willing to provide informed consent (or consent of a guardian)

You may not qualify if…

• Contraindication to MRI
• Contraindication to bevacizumab therapy
• Concurrent enrollment in other neuroimaging trials
• Prior therapy with bevacizumab
• Known hypersensitivity to MRI contrast
• Females who are nursing or pregnant

Where it is running

• Medical University of South Carolina — Charleston, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.